Julián Alejandro Rivillas/LinkedIn
Oct 24, 2025, 12:08
Julián Alejandro Rivillas Compares Tenecteplase to Low-dose Alteplase: TRACE-5 Interim Phase II Results
Julián Alejandro Rivillas, Stroke Fellow at University of Montreal Hospital Center, shared on LinkedIn:
”DAY 1: TRACE-5: Tenecteplase improved 90-day functional outcomes and early reperfusion compared with low-dose alteplase, with no safety difference — interim phase II results.”
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Aug 8, 2026, 06:31A New European Programme in Clinical Haemostasis – CRH French Reference Center for Hemophilia Lyon
-
Aug 8, 2026, 05:23Mohsin Naseer։ From Beginner to Published Researcher
-
Aug 8, 2026, 04:50Marc Carrier: Celebrating 20 Years with ASH CRTI
-
Aug 8, 2026, 04:37Megan Adediran: Building Confidence for a Life Beyond Haemophilia
-
Aug 8, 2026, 04:32Megan Kavanaugh Roussos: Airborne Medical Expands Portfolio with WoundClot Advanced Hemostatic Technology
-
Aug 8, 2026, 04:25Maymoon Madkhali։ First Report of a Rare D– – Blood Phenotype in Saudi Arabia
-
Aug 8, 2026, 04:13Alexandra Bernal: Uncovering the Anticoagulant Role of Factor V in Hemophilia A
-
Aug 8, 2026, 04:03Wellington Fernandes: Honored to Join the Faculty of Medicine of USP as Professor of Hematology
-
Aug 8, 2026, 04:01Noa Ezra: How Senescent Cardiac Cells Drive a Pro-Thrombotic State